The Latest Breaking News from Omicron

Pfizer starts Omicron-specific COVID-19 vaccine trial

The trial will involve 1,420 people aged 18-55.

The Hindu · Jan 25, 2022

Anthony Fauci says Omicron-specific COVID-19 vaccine may be prudent but not needed, as clinical trials announced

A COVID-19 vaccine specifically targeting the Omicron variant would be "prudent", even if it ultimately may not be needed, the top US infectious disease official says, as Pfizer announces trials for such a vaccine.

ABC News · Jan 25, 2022

Mandatory jabs for NHS workers kept under review, says Javid

77,000 NHS staff are yet to be vaccinated.

The Independent UK · Jan 25, 2022

Kroger Stock Falls On Wells Fargo Downgrade

Wells Fargo analyst Edward Kelly downgraded Kroger Co (NYSE:KR) to Underweight from Equal Weight with a $42 price target, implying a 9% downside. The analyst notes the risk/reward for this COVID beneficiary now looks skewed to the downside. While he expects Q4 earnings to exceed consensus once again as Omicron extends what has arguably been…

Benzinga · Jan 25, 2022

UK records 439 Covid deaths - highest since February last year as 94,326 cases recorded

The UK seems to have turned the corner on the Omicron wave with cases far from their New Year peak as restrictions and guidance is loosened across the home nations - but deaths still remain high

Daily Mirror · Jan 25, 2022

Pfizer and BioNTech launch clinical trial for Omicron-specific vaccine

Pfizer Inc and BioNTech have announced the start a clinical trial to test a new version of their vaccine specifically designed to target the Omicron variant of Covid-19 Omicron variant.

Evening Standard · Jan 25, 2022

FDA revokes approval for Covid antibody drugs that don’t work against Omicron prompting DeSantis pushback

Florida governor pushes back against decision, calling it ‘sudden and reckless’

The Independent UK · Jan 25, 2022

Sturgeon relaxes work from home rules

Government guidance changes due to progress in tackling the spread of Omicron

Insider UK · Jan 25, 2022

MakeMyTrip Registers 70.5% Sequential Revenue Growth In Q3

MakeMyTrip Ltd (NASDAQ:MMYT) reported third-quarter FY22 sales growth of 102.5% Y/Y and 70.5% Q/Q, to $115.02 million, beating the analyst consensus of $112.35 million. Gross bookings for the quarter increased 93.0% Y/Y and 57.4% Q/Q. Adjusted EPS of $0.12 beat the analyst consensus of $(0.01). Revenue from Air ticketing increased 50.6% Y/Y, Hotels…

Benzinga · Jan 25, 2022

Inflation and Omicron will dent world growth in 2022, says IMF

Global growth downgraded to 4.4% as body predicts especially marked slowdown for US and China

The Guardian - UK · Jan 25, 2022